Condition
Willis-Ekbom Disease
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 4 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02929732Not ApplicableRecruitingPrimary
Analysis of Sympathetic Activity in Willis-Ekbom Disease
NCT03249779Not ApplicableCompleted
Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation
NCT01976871Phase 4Completed
Switching From Oral Dopamine Agonists to Rotigotine
Showing all 3 trials